CN116376896A - A kit, preparation method and extraction method for extracting plasma free DNA - Google Patents
A kit, preparation method and extraction method for extracting plasma free DNA Download PDFInfo
- Publication number
- CN116376896A CN116376896A CN202310297944.9A CN202310297944A CN116376896A CN 116376896 A CN116376896 A CN 116376896A CN 202310297944 A CN202310297944 A CN 202310297944A CN 116376896 A CN116376896 A CN 116376896A
- Authority
- CN
- China
- Prior art keywords
- buffer
- hcl
- tris
- negative pressure
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1003—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Plant Pathology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
本发明涉及一种提取血浆游离DNA的试剂盒、制备方法及提取方法,包括:1.蛋白酶K:血浆样本中与蛋白酶K的质量/体积比为5:1‑10:1,蛋白酶K的浓度范围为10mg/mL‑30mg/mL;裂解缓冲液:1‑4.5M异硫氰酸胍、1‑6mM EDTA、20‑150mM Tris‑HCl、0.05%‑20%NP40,pH为4‑6;结合缓冲液:1‑4M异硫氰酸胍、1‑3M盐酸胍、20‑150mM Tris‑HCl、1‑6mM EDTA、0.05%‑30% Tween20、10%‑30% PEG 8000、10%‑35%异丙醇,pH为4‑6;漂洗缓冲液1:1‑3M盐酸胍、20‑150mM Tris‑HCl、0.05%‑30% Tween20、10%‑35%无水乙醇,pH为5‑7;漂洗缓冲液2:20‑150mM Tris‑HCl、1‑6mM EDTA、30%‑60%无水乙醇,pH为5‑8;洗脱缓冲液为无酶水、灭菌水中的一种。本发明操作简单快速,可进行微量提取,提取核酸纯度高,不含检测抑制剂,成本低。
The present invention relates to a kit, a preparation method and an extraction method for extracting plasma free DNA, comprising: 1. Proteinase K: The mass/volume ratio of proteinase K in plasma samples is 5:1‑10:1, and the concentration range of proteinase K is 10mg/mL‑30mg/mL; lysis buffer: 1‑4.5M guanidine isothiocyanate , 1‑6mM EDTA, 20‑150mM Tris‑HCl, 0.05%‑20% NP40, pH 4‑6; binding buffer: 1‑4M guanidine isothiocyanate, 1‑3M guanidine hydrochloride, 20‑150mM Tris‑ HCl, 1‑6mM EDTA, 0.05%‑30% Tween20, 10%‑30% PEG 8000, 10%‑35% isopropanol, pH 4‑6; Wash Buffer 1: 1‑3M Guanidine HCl, 20‑ 150mM Tris‑HCl, 0.05%‑30% Tween20, 10%‑35% ethanol, pH 5‑7; Wash Buffer 2: 20‑150mM Tris‑HCl, 1‑6mM EDTA, 30%‑60% None Water ethanol, pH 5‑8; elution buffer is one of enzyme-free water and sterilized water. The invention is simple and fast in operation, can perform micro-extraction, has high purity of extracted nucleic acid, does not contain detection inhibitors, and has low cost.
Description
技术领域technical field
本发明涉及生物技术领域,具体涉及了一种提取血浆游离DNA的试剂盒、制备方法及提取方法。The invention relates to the field of biotechnology, in particular to a kit for extracting plasma free DNA, a preparation method and an extraction method.
背景技术Background technique
游离DNA(cell-free DNA,cfDNA)是一种血液或体液中游离于细胞之外的DNA。1947年,Mandel和Metais首次报道了外周血中存在cfDNA。生理情况下,血液中的cfDNA主要来源于白细胞的坏死和凋亡,在某些疾病和特殊状态下,其他细胞也会释放游离DNA进入血浆,包括来源于肿瘤细胞的循环肿瘤DNA(Circulating tumor DNA,ctDNA),来源于胎儿的cfDNA等。1994年,Vasioukhin等和Sorenson等在急性髓性淋巴瘤、骨髓增生异常综合征和胰腺癌患者外周血ctDNA中发现了RAS基因的突变,表明可以利用ctDNA发现肿瘤的特异性基因突变。随着新的研究结果的不断出现,cfDNA用于疾病早期诊断、预后评估、疗效监测等方面的潜在价值越来越受到关注。检测血浆或血清中cfDNA可视为一种"液体活检",有利于开展各种相关诊断,并能避免有创的组织活检。以血液为检测标本,使重复采集检测样本成为了可能,从而有利于对疾病的发展及肿瘤的治疗过程进行跟踪监测。Free DNA (cell-free DNA, cfDNA) is a kind of DNA free from cells in blood or body fluids. In 1947, Mandel and Metais first reported the presence of cfDNA in peripheral blood. Under physiological conditions, cfDNA in the blood mainly comes from the necrosis and apoptosis of white blood cells. In some diseases and special conditions, other cells will also release free DNA into the plasma, including circulating tumor DNA (circulating tumor DNA) from tumor cells. , ctDNA), cfDNA derived from the fetus, etc. In 1994, Vasioukhin et al. and Sorenson et al. found mutations of the RAS gene in peripheral blood ctDNA of patients with acute myeloid lymphoma, myelodysplastic syndrome, and pancreatic cancer, indicating that ctDNA can be used to discover tumor-specific gene mutations. With the continuous emergence of new research results, the potential value of cfDNA in the early diagnosis of diseases, prognosis evaluation, and efficacy monitoring has attracted more and more attention. The detection of cfDNA in plasma or serum can be regarded as a kind of "liquid biopsy", which is conducive to various related diagnoses and can avoid invasive tissue biopsy. Using blood as a test sample makes it possible to collect test samples repeatedly, which is conducive to tracking and monitoring the development of the disease and the treatment process of the tumor.
目前cfDNA检测对方法学要求极高,虽然目前cfDNA的检测方法都具有很高的敏感度和特异度,但是仍存在一些和传统病理学或细胞遗传学检测结果不一致的情况。由于血浆中存在的靶cfDNA微乎其微,标本的采集、抗凝剂使用和保存的不当都会影响检测的质量,造成假阳性或假阴性的结果所以,优化提取和检测的方法,进一步提高检测cfDNA方法的灵敏度和特异性,缩短检测的时间,降低检测的成本,同时实现检测方法之间的标准化,都是亟待解决的问题。At present, cfDNA detection requires extremely high methodology. Although the current cfDNA detection methods have high sensitivity and specificity, there are still some inconsistencies with traditional pathological or cytogenetic detection results. Since the target cfDNA in the plasma is negligible, improper collection of specimens, use of anticoagulants and storage will affect the quality of the test, resulting in false positive or false negative results. Therefore, the extraction and detection methods should be optimized to further improve the detection of cfDNA. Sensitivity and specificity, shortening the time of detection, reducing the cost of detection, and at the same time achieving standardization among detection methods are all problems that need to be solved urgently.
发明内容Contents of the invention
本发明的目的在于提供一种提取血浆游离DNA的试剂盒、制备方法及提取方法技术,以解决上述背景技术中提出的问题。The object of the present invention is to provide a kit, preparation method and extraction method technology for extracting plasma free DNA, so as to solve the problems raised in the above-mentioned background technology.
为实现上述目的,本发明提供如下技术方案:To achieve the above object, the present invention provides the following technical solutions:
第一方面,本发明提供一种粪便样本DNA核酸提取试剂盒,试剂盒主要包括以下组分:蛋白酶K、裂解缓冲液、结合缓冲液、漂洗缓冲液1、漂洗缓冲液2、洗脱缓冲液。In the first aspect, the present invention provides a DNA nucleic acid extraction kit from a stool sample, the kit mainly includes the following components: proteinase K, lysis buffer, binding buffer,
蛋白酶K:Proteinase K:
蛋白酶K属于丝氨酸蛋白酶SB超家族中的S8家族,由一条肽链组成,具有很高的切割活性,底物识别位点能和底物组成一个3股的反平行β片层,可催化脂肪族氨基酸和芳香族氨基酸的羧基端肽键断裂。此酶经纯化去除了RNA酶和DNA酶活性。蛋白酶K在pH 4-12.5较广的pH范围内均有活性,作用温度范围为37-65℃。Proteinase K belongs to the S8 family in the SB superfamily of serine proteases. It consists of a peptide chain with high cleavage activity. The substrate recognition site can form a 3-strand antiparallel β sheet with the substrate, which can catalyze aliphatic Carboxy-terminal peptide bond cleavage of amino acids and aromatic amino acids. The enzyme is purified to remove RNase and DNase activity. Proteinase K is active in a wide pH range of pH 4-12.5, and the action temperature range is 37-65°C.
蛋白酶K血浆样本中与蛋白酶K的质量/体积比为5:1-10:1,蛋白酶K的浓度范围为10mg/mL-30mg/mL。The mass/volume ratio of proteinase K in the plasma sample to proteinase K is 5:1-10:1, and the concentration range of proteinase K is 10mg/mL-30mg/mL.
优选的,待处理样本与蛋白酶K的体积比为10:1,所述蛋白酶K的浓度范围为20mg/mL。Preferably, the volume ratio of the sample to be treated to the proteinase K is 10:1, and the concentration range of the proteinase K is 20 mg/mL.
裂解缓冲液:Lysis buffer:
裂解缓冲液包括:1-4.5M异硫氰酸胍、1-6mM EDTA、20-150mM Tris-HCl、0.05%-20%NP40,pH为4-6。The lysis buffer includes: 1-4.5M guanidine isothiocyanate, 1-6mM EDTA, 20-150mM Tris-HCl, 0.05%-20% NP40, pH 4-6.
优选的,裂解缓冲液中的成分含量为:4M异硫氰酸胍,6mM EDTA,100mM Tris-HCl,10% NP40,裂解液的pH为5.5。Preferably, the content of components in the lysis buffer is: 4M guanidine isothiocyanate, 6mM EDTA, 100mM Tris-HCl, 10% NP40, and the pH of the lysis solution is 5.5.
本发明提供的裂解缓冲液在裂解血浆样本时,使样品中的核酸游离在裂解体系中,促进核酸与蛋白分离,从而释放核酸。When the lysis buffer provided by the present invention lyses a plasma sample, the nucleic acid in the sample is freed in the lysis system, and the separation of nucleic acid and protein is promoted, thereby releasing the nucleic acid.
具体原理介绍如下:The specific principles are as follows:
异硫氰酸胍:白色结晶性粉末,异硫氰酸胍是一类强力的蛋白质变性剂,无RNA酶和DNA酶活性。在核酸提取中,异硫氰酸胍能够迅速破碎细胞或病毒释放核酸,抑制细胞释放出的核酸酶,保证核酸一级结构的完整性。Guanidine isothiocyanate: white crystalline powder, guanidine isothiocyanate is a powerful protein denaturant, without RNase and DNase activity. In nucleic acid extraction, guanidine isothiocyanate can rapidly break cells or viruses to release nucleic acids, inhibit nucleases released from cells, and ensure the integrity of the primary structure of nucleic acids.
EDTA:即乙二胺四乙酸,其能够与Mg2+、Ca2+、Mn2+、Fe2+等金属离子结合,可防止金属离子激活蛋白酶,从而减少金属离子对核酸质量的影响。EDTA: Ethylenediaminetetraacetic acid, which can combine with metal ions such as Mg2+, Ca2+, Mn2+, Fe2+, etc., can prevent metal ions from activating protease, thereby reducing the impact of metal ions on nucleic acid quality.
Tris-HCl:有助于在细胞裂解和提取过程中保持pH稳定,维持核酸磷酸基团与硅胶膜的带电状态,利氢键的保持,防止核酸被破坏。Tris-HCl: helps to keep the pH stable during cell lysis and extraction, maintain the charged state of the nucleic acid phosphate group and the silica membrane, facilitate the maintenance of hydrogen bonds, and prevent the nucleic acid from being destroyed.
NP40:是一种温和的非离子型去垢剂,1%浓度基本可以破坏掉细胞膜,而对核膜的破坏作用较弱,结合特定的缓冲液可以获得胞浆蛋白。与蛋白结合力强,用于防止物质分子疏水间相互作用,确保蛋白的充分溶解和结构稳定。尤其用于膜蛋白的非变性条件下的溶解从而释放核酸。NP40: It is a mild non-ionic detergent, 1% concentration can basically destroy the cell membrane, but the damage to the nuclear membrane is weak, combined with a specific buffer can obtain cytoplasmic proteins. It has a strong binding force with protein and is used to prevent the interaction between the hydrophobic molecules of the substance and ensure the full dissolution and structural stability of the protein. Especially for solubilization under non-denaturing conditions of membrane proteins to release nucleic acids.
结合缓冲液binding buffer
结合缓冲液,包括:1-4M异硫氰酸胍、1-3M盐酸胍、20-150mM Tris-HCl、1-6mMEDTA、0.05%-30% Tween20、10%-30% PEG 8000、10%-35%异丙醇,pH为4-8。Binding buffer, including: 1-4M guanidine isothiocyanate, 1-3M guanidine hydrochloride, 20-150mM Tris-HCl, 1-6mM EDTA, 0.05%-30% Tween20, 10%-30%
优选的,结合缓冲液中的成分含量为:4M异硫氰酸胍,2M盐酸胍,100m Tris-HCl,4mMEDTA,0.10%Tween20,10%PEG 8000,30%异丙醇,其pH为7.5。Preferably, the content of the components in the binding buffer is: 4M guanidine isothiocyanate, 2M guanidine hydrochloride, 100m Tris-HCl, 4mMEDTA, 0.10% Tween20, 10%
具体原理介绍如下:The specific principles are as follows:
盐酸胍:是核酸酶的强抑制剂,但并不是强变性剂,它在核酸提取中的主要作用是使蛋白质变性并抑制酶活性。盐酸胍能够快速破坏细胞膜,使得蛋白质变性沉淀,从而让核酸能够摆脱蛋白质的缠绕。Guanidine Hydrochloride: It is a strong inhibitor of nuclease, but not a strong denaturant. Its main function in nucleic acid extraction is to denature proteins and inhibit enzyme activity. Guanidine hydrochloride can quickly destroy the cell membrane, denature and precipitate proteins, so that nucleic acids can get rid of the entanglement of proteins.
Tween20(吐温):为非离子型表面活性剂,用来破坏细胞膜(裂解细胞)以释放细胞内的可溶性物质。它们可以破坏蛋白质-蛋白质、蛋白质-脂质、脂质-脂质之间的连接,使蛋白质发生结构上的变性,去除与核酸相互作用的蛋白质。Tween20 (Tween): It is a non-ionic surfactant used to destroy cell membranes (lyse cells) to release soluble substances in cells. They can disrupt protein-protein, protein-lipid, and lipid-lipid connections, structurally denature proteins, and remove proteins that interact with nucleic acids.
PEG 8000(聚氧乙烯8000):在空气中易发生氧化降解,需尽量避免将其暴露在空气和或高温环境,活化后可以结合多肽或蛋白质,用于沉淀蛋白,原理是通过空间位置排斥,使蛋白质被迫集聚在—起而引起沉淀的发生。PEG 8000 (Polyoxyethylene 8000): It is prone to oxidative degradation in the air, and it should be avoided to expose it to the air and or high temperature environment. After activation, it can be combined with peptides or proteins to precipitate proteins. The principle is through spatial repulsion, The protein is forced to gather together and cause precipitation.
异丙醇:能够夺取RNA/DNA周围的水分,因此RNA/DNA能够聚集而发生沉淀。Isopropanol: It can capture the moisture around RNA/DNA, so RNA/DNA can aggregate and precipitate.
漂洗缓冲液1
漂洗缓冲液1,包括:1-3M盐酸胍、20-150mM Tris-HCl、0.05%-30% Tween20、10%-35%无水乙醇,pH为5-8。
优选的,漂洗缓冲液1的组成成分为:2M盐酸胍,50mM Tris-HCl,10% Tween20,35%乙醇,pH为8.0。Preferably, the composition of the
漂洗缓冲液2
漂洗缓冲液2,包括:20-150mMTris-HCl、1-6mMEDTA、30%-60%无水乙醇,pH为5-8。
优选的,漂洗缓冲液2的组成成分为:100mM Tris-HCl,4mM EDTA,60%乙醇,pH8.0。用于洗去残留的盐离子和胍盐,以免对核酸提取后的后续分子生物学实验产生不利影响。Preferably, the composition of the
洗脱缓冲液Elution buffer
洗脱缓冲液为无酶水、灭菌水中的一种。The elution buffer is one of enzyme-free water and sterilized water.
第二方面,本发明提供一种提取血浆游离DNA的试剂盒的制备方法,包括以下步骤:In a second aspect, the present invention provides a method for preparing a kit for extracting plasma free DNA, comprising the following steps:
A.获取蛋白酶K;A. Obtain proteinase K;
B.裂解缓冲液制备:在去离子水中加入所述异硫氰酸胍、Tris-HCl、EDTA和NP40,并使各组分溶解混匀,从而得到混合物,调节所述混合物的pH至4-6;B. Preparation of lysis buffer: add the guanidine isothiocyanate, Tris-HCl, EDTA and NP40 in deionized water, and dissolve and mix the components to obtain a mixture, adjust the pH of the mixture to 4- 6;
C.结合缓冲液制备:在去离子水中加入所述异硫氰酸胍、盐酸胍、Tris-HCl、EDTA、PEG 8000、异丙醇和Tween-20,并使各组分溶解混匀,从而得到混合物,调节所述混合物的pH至4-8。C. Preparation of binding buffer: add the guanidine isothiocyanate, guanidine hydrochloride, Tris-HCl, EDTA, PEG 8000, isopropanol and Tween-20 in deionized water, and dissolve and mix the components to obtain mixture, adjusting the pH of the mixture to 4-8.
D.漂洗缓冲液1制备:在去离子水中加入所述盐酸胍,Tris-HCl、Tween20,无水乙醇,并使各组分溶解混匀,从而得到混合物,调节所述混合物的pH至5-8。D. Preparation of rinsing buffer 1: add the guanidine hydrochloride, Tris-HCl, Tween20, absolute ethanol to deionized water, and dissolve and mix the components to obtain a mixture, adjust the pH of the mixture to 5- 8.
E.漂洗缓冲液2制备:在去离子水中加入所述Tris-HCl、EDTA和无水乙醇,并使各组分溶解混匀,从而得到混合物,调节所述混合物的pH至5-8。E. Preparation of rinsing buffer 2: adding the Tris-HCl, EDTA and absolute ethanol to deionized water, and dissolving and mixing each component to obtain a mixture, and adjusting the pH of the mixture to 5-8.
F.洗脱缓冲液为无酶水、灭菌水中的一种。F. The elution buffer is one of enzyme-free water and sterilized water.
第三方面。本发明提供一种提取血浆游离DNA的试剂盒的提取方法,包括以下步骤:third aspect. The invention provides an extraction method of a kit for extracting plasma free DNA, comprising the following steps:
A.样本裂解A. Sample Lysis
血浆或样本:向离心管(自备)中加入1ml血清/血浆样本,若样本不足1ml,加入PBS溶液补至1ml体积,向以上溶液中加入100ul蛋白酶K,混匀,加入800ul裂解缓冲液,剧烈震荡至少30秒;Plasma or sample: add 1ml serum/plasma sample to a centrifuge tube (prepared by yourself), if the sample is less than 1ml, add PBS solution to make up to 1ml volume, add 100ul proteinase K to the above solution, mix well, add 800ul lysis buffer, Shake vigorously for at least 30 seconds;
B.吸附结合B. Adsorption binding
60℃孵育30分钟,其间颠倒混匀,加入1800ul结合缓冲液,颠倒混匀10次或剧烈震荡15-30秒,冰浴5分钟,正确连接负压装置,将连接管插到负压装置的插口上,将吸附柱插入到连接管上,将延伸管插入开盖的吸附柱中,将冰浴后的混合溶液全部加入延伸管中,开启并调节负压至-900~-800mbar,缓慢吸走管中溶液。待溶液完全吸走,关闭负压开关,当压力恢复至0mbar时,小心移去延伸管;Incubate at 60°C for 30 minutes, mix by inverting, add 1800ul of binding buffer, invert and mix 10 times or shake vigorously for 15-30 seconds, bathe in ice for 5 minutes, connect the negative pressure device correctly, insert the connecting tube into the negative pressure device On the socket, insert the adsorption column into the connecting tube, insert the extension tube into the adsorption column with the cover removed, add all the mixed solution after the ice bath into the extension tube, turn on and adjust the negative pressure to -900~-800mbar, slowly suck Take the solution in the tube. After the solution is completely absorbed, turn off the negative pressure switch, and when the pressure returns to 0mbar, carefully remove the extension tube;
C.漂洗C. Rinse
向吸附柱中加入500ul漂洗缓冲液1,开启并调节负压至-900~-800mbar,待溶液完全吸走,关闭负压开关;向吸附柱中加入750ul漂洗缓冲液2,开启并调节负压至-900~-800mbar,待溶液完全吸走,关闭负压开关;向吸附柱中加入750ul无水乙醇,开启并调节负压至-800~-900mbar,待溶液完全吸走,关闭负压开关;当压力恢复至0mbar时,将吸附柱取下,置于新的收集管中,12,000rpm离心3分钟,倒掉收集管中的废液;Add 500ul rinse
D.洗脱D. Elution
将吸附柱置于室温数分钟,以彻底晾干。将吸附柱置于新的1.5ml离心管中,向吸附柱的中间部位悬空加入20-150ul洗脱缓冲液,室温放置3分钟,12,000rpm离心1分钟,收集DNA溶液,-20℃保存DNA。Allow the column to dry completely at room temperature for several minutes. Place the adsorption column in a new 1.5ml centrifuge tube, add 20-150ul of elution buffer to the middle of the adsorption column, place at room temperature for 3 minutes, centrifuge at 12,000rpm for 1 minute, collect the DNA solution, and store the DNA at -20°C.
与现有技术比,本发明达到的有益效果是:Compared with prior art, the beneficial effect that the present invention reaches is:
(1)操作简单快速,可进行微量提取:试剂盒可与负压装置匹配使用,其操作简便,省去传统的离心步骤,直接利用负压装置抽提,能够快速高效提取血浆中的游离核酸,使得利用少量血浆样本即可获得较高纯度和得率的核酸,满足后续核酸检测用量。(1) The operation is simple and fast, and can be used for micro-extraction: the kit can be used with a negative pressure device, which is easy to operate, saves the traditional centrifugation step, and directly uses the negative pressure device for extraction, which can quickly and efficiently extract free nucleic acids in plasma , so that a small amount of plasma samples can be used to obtain nucleic acids with higher purity and yield, which can meet the amount of subsequent nucleic acid detection.
(2)提取核酸纯度高,不含检测抑制剂:提取的核酸不含核酸酶及检测抑制剂,DNA保存时间长,后续运用于PCR、荧光定量PCR和二代测序等分子生物学实验,利于血浆样本核酸的保存和检测。(2) The extracted nucleic acid has high purity and does not contain detection inhibitors: the extracted nucleic acid does not contain nucleases and detection inhibitors, and the DNA is stored for a long time. It is subsequently used in molecular biology experiments such as PCR, fluorescent quantitative PCR and next-generation sequencing, which is beneficial Preservation and detection of nucleic acid in plasma samples.
(3)成本低:试剂盒所有组分均为自主研发,并实现了量产,成本低,可满足分子生物学多领域研究和应用,具有广泛的应用前景和市场推广价值。(3) Low cost: All components of the kit are self-developed and mass-produced. The cost is low, and it can meet the research and application in multiple fields of molecular biology. It has broad application prospects and market promotion value.
附图说明Description of drawings
图1为本发明提取试剂不同批次吸附柱富集效果图;Fig. 1 is the enrichment effect figure of adsorption column of different batches of extraction reagent of the present invention;
图2为本发明不同批次提取试剂提取效果图;Fig. 2 is the extraction effect diagram of different batches of extraction reagents of the present invention;
图3为本发明实验组试剂盒(康为)与对比组(凯杰)提取cfDNA浓度对比图;Figure 3 is a comparison chart of cfDNA concentration extracted from the experimental group kit (Kangwei) and the comparison group (Qiajie) of the present invention;
图4为本发明实验组试剂盒(康为)与对比组(凯杰)提取cfDNA荧光定量对比图;Fig. 4 is a comparison chart of cfDNA fluorescence quantification extracted from the experimental group kit (Kangwei) and the comparison group (Qiajie) of the present invention;
图5为本发明实验组试剂盒(康为)与对比组(凯杰)文库对比图;Fig. 5 is the comparison diagram of the libraries of the experimental group kit (Kangwei) and the comparison group (Qiajie) of the present invention;
图6为本发明实验组试剂盒(康为)与对比组(凯杰)测序mapped对比图;Fig. 6 is a comparison chart of the sequence mapping between the experimental group kit (Kangwei) and the comparison group (Qiagen) of the present invention;
图7为本发明实验组试剂盒(康为)与对比组(凯杰)测序rmdup对比图;Fig. 7 is the comparison chart of the sequencing rmdup of the experimental group kit (Kangwei) and the comparison group (Qiagen) of the present invention;
具体实施方式Detailed ways
为了能够更加详尽地了解本发明的特点与技术内容,下面结合附图对本发明的实现进行详细阐述,所附附图仅供参考说明之用,并非用来限定本发明。In order to understand the characteristics and technical content of the present invention in more detail, the implementation of the present invention will be described in detail below in conjunction with the accompanying drawings. The attached drawings are only for reference and description, and are not intended to limit the present invention.
实施例1.Example 1.
本实施例提供一种血浆样本DNA核酸提取试剂盒及制备方法。该试剂盒包括蛋白酶K、裂解缓冲液、结合缓冲液、漂洗缓冲液1、漂洗缓冲液2、洗脱缓冲液。This embodiment provides a plasma sample DNA nucleic acid extraction kit and a preparation method. The kit includes proteinase K, lysis buffer, binding buffer,
本实施例中,试剂盒各试剂组分如下:In this embodiment, each reagent component of the kit is as follows:
蛋白酶K为20mg/mL;Proteinase K is 20mg/mL;
裂解缓冲液:1-4.5M异硫氰酸胍、1-6mM EDT、20-150mM Tris-HCl 0.05%-20%NP40,pH为5.5;Lysis buffer: 1-4.5M guanidine isothiocyanate, 1-6mM EDT, 20-150mM Tris-HCl 0.05%-20% NP40, pH 5.5;
结合缓冲液:4M异硫氰酸、2M盐酸胍、100m Tris-HCl、4mM EDTA、0.10%Tween20、10%PEG 8000、30%异丙醇,其pH为7.5;Binding buffer: 4M isothiocyanate, 2M guanidine hydrochloride, 100m Tris-HCl, 4mM EDTA, 0.10% Tween20, 10
漂洗缓冲液1:2M盐酸胍、50mM Tris-HCl、10% Tween20、35%乙醇,pH为8.0;Wash buffer 1: 2M guanidine hydrochloride, 50mM Tris-HCl, 10% Tween20, 35% ethanol, pH 8.0;
漂洗缓冲液2:100mM Tris-HCl、4mM EDTA、60%乙醇,pH为8.0;Wash buffer 2: 100mM Tris-HCl, 4mM EDTA, 60% ethanol, pH 8.0;
洗脱缓冲液为无酶水、灭菌水中的一种。The elution buffer is one of enzyme-free water and sterilized water.
实施例2.血浆样本DNA提取方法(柱式法提取)Example 2. Plasma sample DNA extraction method (column method extraction)
采用实施例1中制备的血浆提取试剂盒试剂进行血浆样本DNA核酸提取。The plasma extraction kit reagents prepared in Example 1 were used to extract DNA and nucleic acid from plasma samples.
柱式法提取具体步骤如下:The specific steps of column method extraction are as follows:
1.样本裂解1. Sample Lysis
血浆或样本:向离心管(自备)中加入1ml血清/血浆样本,若样本不足1ml,加入PBS溶液补至1ml体积。向以上溶液中加入100ul蛋白酶K,混匀。加入800ul裂解缓冲液,剧烈震荡至少30秒。Plasma or sample: add 1ml serum/plasma sample to a centrifuge tube (prepared by yourself), if the sample is less than 1ml, add PBS solution to make up to 1ml volume. Add 100ul proteinase K to the above solution and mix well. Add 800ul lysis buffer and shake vigorously for at least 30 seconds.
2.吸附结合2. Adsorption binding
60℃孵育30分钟,其间颠倒混匀数次。加入1800ul结合缓冲液,颠倒混匀10次或剧烈震荡Incubate at 60°C for 30 minutes, mixing by inverting several times. Add 1800ul binding buffer, invert and mix 10 times or shake vigorously
15-30秒。冰浴5分钟。正确连接负压装置,将连接管插到负压装置的插口上。将吸附柱插入到连接管上。将延伸管插入开盖的吸附柱中。将冰浴后的混合溶液全部加入延伸管中,开启并调节负压至-900~-800mbar,缓慢吸走管中溶液。待溶液完全吸走,关闭负压开关,当压力恢复至0mbar时,小心移去延伸管。15-30 seconds. Ice bath for 5 minutes. Correctly connect the negative pressure device, and insert the connecting tube into the socket of the negative pressure device. Insert the adsorption column into the connecting tube. Insert the extension tube into the decapped adsorption column. Add all the mixed solution after ice bath into the extension tube, turn on and adjust the negative pressure to -900~-800mbar, and slowly suck the solution in the tube. After the solution is completely absorbed, turn off the negative pressure switch, and when the pressure returns to 0mbar, carefully remove the extension tube.
3.漂洗3. Rinse
向吸附柱中加入500ul漂洗缓冲液1,开启并调节负压至-900~-800mbar,待溶液完全吸走,关闭负压开关。向吸附柱中加入750ul漂洗缓冲液2,开启并调节负压至-900~-800mbar,待溶液完全吸走,关闭负压开关。向吸附柱中加入750ul无水乙醇,开启并调节负压至-800~-900mbar,待溶液完全吸走,关闭负压开关。当压力恢复至0mbar时,将吸附柱取下,置于新的收集管中,12,000rpm离心3分钟,倒掉收集管中的废液。Add 500ul of
4.洗脱4. Elution
将吸附柱置于室温数分钟,以彻底晾干。将吸附柱置于新的1.5ml离心管中,向吸附柱的中间部位悬空加入20-150ul洗脱缓冲液,室温放置3分钟,12,000rpm离心1分钟,收集DNA溶液,-20℃保存DNA。Allow the column to dry completely at room temperature for several minutes. Place the adsorption column in a new 1.5ml centrifuge tube, add 20-150ul of elution buffer to the middle of the adsorption column, place at room temperature for 3 minutes, centrifuge at 12,000rpm for 1 minute, collect the DNA solution, and store the DNA at -20°C.
实施例3.测试不同吸附柱提取效果Example 3. Test the extraction effect of different adsorption columns
实验材料:血浆样本;实施例1中制备的血浆样本提取试剂,其中吸附柱分别选用国产吸附柱1、国产吸附柱2和进口吸附柱Experimental materials: plasma samples; plasma sample extraction reagents prepared in Example 1, wherein the adsorption columns were selected from
实验方法:取4等份(各1ml)新鲜血浆样本分装于干净的离心管中,分别加入100μl蛋白酶K,混匀,加入800μl裂解缓冲液,剧烈震荡至少30秒。60℃孵育30分钟,其间颠倒混匀数次。加入1800μl结合缓冲液,颠倒混匀10次或剧烈震荡15-30秒。冰浴5分钟后连接负压装置,使用三种吸附柱进行核酸吸附,漂洗缓冲液1、漂洗缓冲液2、无水乙醇分别进行漂洗后进行离心晾干,加入洗脱缓冲液洗脱。Experimental method: Take 4 equal parts (1ml each) of fresh plasma samples and divide them into clean centrifuge tubes, add 100μl proteinase K, mix well, add 800μl lysis buffer, shake vigorously for at least 30 seconds. Incubate at 60°C for 30 minutes, mixing by inverting several times. Add 1800μl binding buffer, mix by inverting 10 times or shake vigorously for 15-30 seconds. After 5 minutes of ice bathing, connect the negative pressure device, use three kinds of adsorption columns for nucleic acid adsorption, rinse
4份样本分为三组,分别进行三种提取处理:(国产吸附柱组1)其中4份采用江苏康为世纪的国产吸附柱进行提取;(国产吸附柱组2)4份血浆样本采用美基生物的国产吸附柱进行提取;(进口吸附柱组)4份血浆样本采用thermo的吸附柱进行提取。The 4 samples were divided into three groups, which were subjected to three extraction treatments: (domestic adsorption column group 1) 4 of them were extracted with Jiangsu Kangwei Century's domestic adsorption column; (domestic adsorption column group 2) 4 plasma samples were extracted with American Bio-based domestic adsorption column for extraction; (imported adsorption column group) 4 plasma samples were extracted with thermo adsorption column.
提取后的DNA使用Qubit2.0检测核酸样本浓度,结果如表1所示,国产吸附柱组提取效果基本相当,使用进口吸附柱提取组提取的核酸浓度略高。The extracted DNA was detected by Qubit2.0 to detect the concentration of nucleic acid samples. The results are shown in Table 1. The extraction effect of the domestic adsorption column group is basically the same, and the concentration of nucleic acid extracted by the imported adsorption column extraction group is slightly higher.
表1.不同吸附柱提取效果比较Table 1. Comparison of extraction effects of different adsorption columns
实施例4.测试不同批次试剂提取效果
实验材料:血浆样本;实施例1中制备的血浆样本提取试剂(不同批次),其中吸附柱选用国产吸附柱1Experimental materials: plasma samples; plasma sample extraction reagents (different batches) prepared in Example 1, wherein the adsorption column is selected from
实验方法:样本采取标准DNA Marker混合血清,使用两个生产批次的国产吸附柱1、提取试剂进行DNA富集分离。使用Qsep100TM全自动核酸蛋白分析系统进行两个批次间的比较。不同批次间的富集分离结果高度一致。如图1和图2所示。Experimental method: Samples were collected from standard DNA Marker mixed serum, and two production batches of
实施例5.血浆样本提取试剂盒提取能力测试Example 5. Plasma Sample Extraction Kit Extraction Ability Test
实验材料:3个志愿者提供的血浆样本。Experimental materials: plasma samples provided by 3 volunteers.
实验组试剂:实施例1中制备的血浆样本提取试剂(采用国产康为吸附柱)Experimental group reagent: plasma sample extraction reagent prepared in Example 1 (adopting domestic Kangwei adsorption column)
对比组试剂:凯杰游离核酸提取试剂盒(QIAamp Circulating Nucleic Acid Kit(50)./ID:55114)Comparative reagents: QIAamp Circulating Nucleic Acid Kit (50)./ID:55114
实验方法:将3个志愿者提供的血浆样本保存于血浆游离DNA保存管中(康为世纪,货号CWY055)Experimental method: The plasma samples provided by 3 volunteers were stored in plasma cell-free DNA preservation tubes (Kangwei Century, Cat. No. CWY055)
(A)实验组试剂-负压装置提取组:分别取两份新鲜血浆样本分装于干净的离心管中,分别进行5ml/8ml提取,(A) Experimental group reagent-negative pressure device extraction group: take two fresh plasma samples and put them in clean centrifuge tubes, and extract 5ml/8ml respectively,
5ml提取:加入1ml蛋白酶K,混匀,加入4ml裂解缓冲液,剧烈震荡至少30秒。60℃孵育30分钟,其间颠倒混匀数次。加入9ml结合缓冲液,颠倒混匀10次或剧烈震荡15-30秒。冰浴5分钟后连接负压装置,使用三种吸附柱进行核酸吸附,漂洗缓冲液1、漂洗缓冲液2、无水乙醇分别进行漂洗后进行离心晾干,加入洗脱缓冲液洗脱。5ml extraction: add 1ml proteinase K, mix well, add 4ml lysis buffer, shake vigorously for at least 30 seconds. Incubate at 60°C for 30 minutes, mixing by inverting several times. Add 9ml binding buffer, mix by inverting 10 times or shake vigorously for 15-30 seconds. After 5 minutes of ice bathing, connect the negative pressure device, use three kinds of adsorption columns for nucleic acid adsorption, wash with rinsing
8ml提取:加入1.6ml蛋白酶K,混匀,加入6.4ml裂解缓冲液,剧烈震荡至少30秒。60℃孵育30分钟,其间颠倒混匀数次。加入14.4ml结合缓冲液,颠倒混匀10次或剧烈震荡15-30秒。冰浴5分钟后连接负压装置,使用三种吸附柱进行核酸吸附,漂洗缓冲液1、漂洗缓冲液2、无水乙醇分别进行漂洗后进行离心晾干,加入洗脱缓冲液洗脱。8ml extraction: add 1.6ml proteinase K, mix well, add 6.4ml lysis buffer, shake vigorously for at least 30 seconds. Incubate at 60°C for 30 minutes, mixing by inverting several times. Add 14.4ml binding buffer, invert and mix 10 times or vigorously shake for 15-30 seconds. After 5 minutes of ice bathing, connect the negative pressure device, use three kinds of adsorption columns for nucleic acid adsorption, wash with rinsing
(B)对比组试剂-负压装置提取组:分别取两份新鲜血浆样本分装于干净的离心管中,分别进行5ml/8ml提取,采用凯杰的游离DNA提取试剂盒(目录号55114)按照说明书操作提取。(B) Reagents of the comparison group - negative pressure device extraction group: take two fresh plasma samples and divide them into clean centrifuge tubes, and extract 5ml/8ml respectively, using Qiagen's free DNA extraction kit (catalogue number 55114) Extract according to the instructions.
提取后的核酸用Qubit2.0进行DNA浓度检测,实验结果如表2所示,实验组-负压装置提取组和对比组-负压装置提取组相比,提取浓度略优,如图3所示。The extracted nucleic acid was tested for DNA concentration with Qubit2.0, and the experimental results are shown in Table 2. Compared with the comparison group-negative pressure device extraction group, the extraction concentration of the experimental group-negative pressure device extraction group was slightly better, as shown in Figure 3 Show.
后续荧光定量PCR检测KTB引物,实验组-负压装置提取组和对比组-负压装置提取组相比,实验结果如表3所示,实验组CT值略低,如图4所示。Subsequent fluorescent quantitative PCR detection of KTB primers, compared with the experimental group-negative pressure device extraction group and the control group-negative pressure device extraction group, the experimental results are shown in Table 3, and the CT value of the experimental group is slightly lower, as shown in Figure 4.
提取完成后使用CW3045S/CW3026S康为建库提取试剂盒进行文库构建,投入用量20ul,华大MGI平台测序,表4为文库构建后Qubit2.0所测文库浓度,如图5所示,实验组提取试剂出库浓度略优于对比组提取试剂,测序结果mapped、rmdup数值也略优,如图6和图7所示。After the extraction was completed, the CW3045S/CW3026S Kangwei Library Extraction Kit was used for library construction, and the input amount was 20ul, and the Huada MGI platform was sequenced. Table 4 shows the concentration of the library measured by Qubit2.0 after library construction. As shown in Figure 5, the experimental group The extraction concentration of the extraction reagent was slightly better than that of the comparison group, and the mapped and rmdup values of the sequencing results were also slightly better, as shown in Figure 6 and Figure 7.
而本实施例提供的实验组血浆核酸提取试剂和方法采用的柱式法,提取浓度相对较高,并且PCR检测Ct值略低,出库浓度略高,可以更好地满足后续核酸检测实验要求。However, the column method used in the experimental group plasma nucleic acid extraction reagents and methods provided in this example has a relatively high extraction concentration, a slightly lower Ct value in PCR detection, and a slightly higher concentration out of the warehouse, which can better meet the requirements of subsequent nucleic acid detection experiments. .
表2.血浆提取试剂盒提取浓度Table 2. Extraction concentration of plasma extraction kit
表3.血浆提取试剂盒提取荧光定量对比Table 3. Fluorescence quantitative comparison of plasma extraction kits
表4.血浆提取试剂盒提取文库对比Table 4. Comparison of libraries extracted by plasma extraction kits
尽管已经示出和描述了本发明的实施例,对于本领域的普通技术人员而言,可以理解在不脱离本发明的原理和精神的情况下可以对这些实施例进行多种变化、修改、替换和变型,本发明的范围由所附权利要求及其等同物限定。Although the embodiments of the present invention have been shown and described, those skilled in the art can understand that various changes, modifications and substitutions can be made to these embodiments without departing from the principle and spirit of the present invention. and modifications, the scope of the invention is defined by the appended claims and their equivalents.
Claims (3)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310297944.9A CN116376896A (en) | 2023-03-24 | 2023-03-24 | A kit, preparation method and extraction method for extracting plasma free DNA |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310297944.9A CN116376896A (en) | 2023-03-24 | 2023-03-24 | A kit, preparation method and extraction method for extracting plasma free DNA |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116376896A true CN116376896A (en) | 2023-07-04 |
Family
ID=86978023
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310297944.9A Pending CN116376896A (en) | 2023-03-24 | 2023-03-24 | A kit, preparation method and extraction method for extracting plasma free DNA |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116376896A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116926064A (en) * | 2023-08-23 | 2023-10-24 | 国药(武汉)精准医疗科技有限公司 | Nucleic acid extraction kit and preparation method and application thereof |
| CN117660437A (en) * | 2023-11-03 | 2024-03-08 | 卡秋(江苏)生物科技有限公司 | A method and kit for extracting and purifying nucleic acids from plasma free nucleic acids and paraffin-embedded tissue sections |
| CN120400128A (en) * | 2025-07-03 | 2025-08-01 | 上海金福康制药工程技术有限公司 | A cfDNA extraction kit and extraction method |
-
2023
- 2023-03-24 CN CN202310297944.9A patent/CN116376896A/en active Pending
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116926064A (en) * | 2023-08-23 | 2023-10-24 | 国药(武汉)精准医疗科技有限公司 | Nucleic acid extraction kit and preparation method and application thereof |
| CN116926064B (en) * | 2023-08-23 | 2024-01-02 | 国药(武汉)精准医疗科技有限公司 | Nucleic acid extraction kit and preparation method and application thereof |
| CN117660437A (en) * | 2023-11-03 | 2024-03-08 | 卡秋(江苏)生物科技有限公司 | A method and kit for extracting and purifying nucleic acids from plasma free nucleic acids and paraffin-embedded tissue sections |
| CN120400128A (en) * | 2025-07-03 | 2025-08-01 | 上海金福康制药工程技术有限公司 | A cfDNA extraction kit and extraction method |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN116376896A (en) | A kit, preparation method and extraction method for extracting plasma free DNA | |
| JP7083756B2 (en) | Protein-based sample recovery matrix and equipment | |
| JP4304348B2 (en) | DNA isolation method | |
| JP4594467B2 (en) | Purification of nucleic acid using paramagnetic particles and its operation method | |
| US8465966B2 (en) | Post protein hydrolysis removal of a potent ribonuclease inhibitor and the enzymatic capture of DNA | |
| CN114107289B (en) | Nucleic acid extraction kit for fecal samples, preparation method and extraction method | |
| JP2013530697A (en) | Nucleic acid extraction from wax-embedded samples | |
| CN107058295B (en) | Whole blood DNA rapid extraction method | |
| CN117285596B (en) | Hexapeptide RL6 with uric acid reducing function and application thereof | |
| JP2006517225A (en) | Chemical treatment of biological samples for nucleic acid extraction and kits for the treatment | |
| CN117285597B (en) | Pentapeptide KK5 with uric acid reducing function and application thereof | |
| CN108026570A (en) | The composition and method of purification of nucleic acid from blood sample | |
| CN111575228A (en) | Immunomagnetic bead separation method capable of obtaining complete exosomes | |
| WO2024240259A1 (en) | Use of formaldehyde heavy crosslinking in cut&tag library construction | |
| JP2021518157A (en) | Method for extracting nucleic acid | |
| US20040029166A1 (en) | Nucleic acid-separating method and nucleic acid-extracting reagent | |
| CN117965527A (en) | Method for extracting free nucleic acid in blood plasma, kit and application thereof | |
| TW201114467A (en) | Method, agent, and kit for isolating nucleic acids | |
| CN103911379A (en) | Nucleic acid aptamer, derivatives, screening method and application thereof | |
| JP6704563B2 (en) | Chaotrope and method for extracting genomic DNA using the chaotrope | |
| CN114058614A (en) | Nucleic acid extraction kit and application thereof, nucleic acid extraction method | |
| CN113801915B (en) | Method for obtaining target RNA of target RNA binding protein | |
| RU2603098C1 (en) | Method for extracting circulating dna from plasma or blood serum | |
| CN115851698B (en) | Blood genome DNA extraction kit and use method thereof | |
| JP2004073193A (en) | Nucleic acid separation method and nucleic acid extraction reagent |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB02 | Change of applicant information |
Country or region after: China Address after: No. 18 Zelan Road, Medical High tech Zone, Taizhou City, Jiangsu Province, 225300 Applicant after: Jiangsu Kangwei century Biotechnology Co.,Ltd. Address before: 225300 4 floor, building TQB, No. 1, Yao Cheng Avenue, Taizhou, Jiangsu. Applicant before: Jiangsu Kangwei century Biotechnology Co.,Ltd. Country or region before: China |
|
| CB02 | Change of applicant information |